The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
In the latest session, Editas Medicine Inc (NASDAQ: EDIT) closed at $2.63 down -3.66% from its previous closing price of $2.73. In other words, the price has decreased by -$3.66 from its previous closing price. On the day, 1.47 million shares were traded. EDIT stock price reached its highest trading level at $2.715 during the session, while it also had its lowest trading level at $2.61.
Ratios:
For a deeper understanding of Editas Medicine Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.77 and its Current Ratio is at 2.77. In the meantime, Its Debt-to-Equity ratio is 4.05 whereas as Long-Term Debt/Eq ratio is at 3.47.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on April 28, 2025, initiated with a Buy rating and assigned the stock a target price of $3.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 07 ’25 when Parison Amy sold 679 shares for $2.58 per share. The transaction valued at 1,752 led to the insider holds 16,827 shares of the business.
Burkly Linda sold 5,121 shares of EDIT for $12,757 on Jul 31 ’25. The EVP, CHIEF SCIENTIFIC OFFICER now owns 64,398 shares after completing the transaction at $2.49 per share. On Jul 31 ’25, another insider, Burkly Linda, who serves as the Officer of the company, bought 7,500 shares for $3.46 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EDIT now has a Market Capitalization of 236490144 and an Enterprise Value of 88116048. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.08 while its Price-to-Book (P/B) ratio in mrq is 11.98. Its current Enterprise Value per Revenue stands at 2.265 whereas that against EBITDA is -0.572.
Stock Price History:
The Beta on a monthly basis for EDIT is 2.16, which has changed by -0.35539216 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, EDIT has reached a high of $4.19, while it has fallen to a 52-week low of $0.91. The 50-Day Moving Average of the stock is 2.21%, while the 200-Day Moving Average is calculated to be 38.14%.
Shares Statistics:
For the past three months, EDIT has traded an average of 2.59M shares per day and 2377690 over the past ten days. A total of 89.92M shares are outstanding, with a floating share count of 89.11M. Insiders hold about 0.90% of the company’s shares, while institutions hold 47.42% stake in the company. Shares short for EDIT as of 1753920000 were 7852628 with a Short Ratio of 3.03, compared to 1751241600 on 8730833. Therefore, it implies a Short% of Shares Outstanding of 7852628 and a Short% of Float of 9.41.
Earnings Estimates
Current recommendations for the stock of the company come from 6.0 analysts. The consensus estimate for the next quarter is -$0.26, with high estimates of $0.11 and low estimates of -$0.75.
Analysts are recommending an EPS of between -$1.68 and -$2.22 for the fiscal current year, implying an average EPS of -$2.03. EPS for the following year is -$1.07, with 8.0 analysts recommending between -$0.63 and -$1.6.
Revenue Estimates
A total of 12 analysts believe the company’s revenue will be $4.94M this quarter.It ranges from a high estimate of $25M to a low estimate of $500k. As of the current estimate, Editas Medicine Inc’s year-ago sales were $61k
A total of 12 analysts have provided revenue estimates for EDIT’s current fiscal year. The highest revenue estimate was $55.74M, while the lowest revenue estimate was $9.2M, resulting in an average revenue estimate of $20.57M. In the same quarter a year ago, actual revenue was $32.31M
